# A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)

> **NCT00209261** · PHASE4 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 221 (actual)

## Conditions studied

- Primary Nocturnal Enuresis

## Interventions

- **DRUG:** MINIRIN Oral Lyophilisate
- **DRUG:** Minirin tablet

## Key facts

- **NCT ID:** NCT00209261
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-08
- **Final completion:** 2005-09
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209261, "A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00209261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*